According to the Zhitong Finance App, Jingfang Pharmaceutical-B (02595.HK) announced interim results for the six months ended June 30, 2026, with revenue of 42.473 million yuan (RMB, same below), a year-on-year decrease of 52.14%; R&D expenses of 193 million yuan, an increase of 57.25%; net loss of 220 million yuan, a year-on-year narrowing of 68.48%; and a basic loss of 0.59 yuan per share.

According to the Zhitong Finance App, Jingfang Pharmaceutical-B (02595.HK) announced interim results for the six months ended June 30, 2026, with revenue of 42.473 million yuan (RMB, same below), a year-on-year decrease of 52.14%; R&D expenses of 193 million yuan, an increase of 57.25%; net loss of 220 million yuan, a year-on-year narrowing of 68.48%; and a basic loss of 0.59 yuan per share.